Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming
October 4th, 2022 | 🕒
https://www.ispeech.org/text.to.speech TOKYO and HENNIGSDORF, Germany, Oct. 3, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and
Gloss